An amine functional compound comprising i. least one segment consisting of at least one ether unit E and at least one ester unit, wherein the ether units and ester units are connected by an ether link or by an ester link, and wherein the sum of the number of ether units and ester units is at least three, and wherein the ether units and ester units are arranged in random order, and ii. at least one amine group ii. selected from a tertiary amine group, a salt of a tertiary amine group and a quaternary ammonium group, wherein the at least one segment is covalently linked to a polymerization starter moiety comprising the at least one amine group ii.

The present invention provides a compound which is a polyether phosphate ester and which does not comprise an alkylene oxide residue. The invention also provides a composition which comprises: i) a polyether phosphate ester; ii) a mono-alcohol phosphate ester; and iii) a polyether which comprises at least two terminal C6 to C36 hydrocarbyl groups. Further aspects of the invention include an emulsion, a personal care formulation, uses and methods comprising the compound or composition of the invention.

Phosphate-containing copolymers, medical compositions containing the phosphate-containing copolymers, and methods of suppressing microbial virulence are provided. By suppressing virulence, administration and/or application of the medical compositions can be used to prevent, mitigate, or treat a microbial infection. The phosphate-containing copolymers are prepared by phosphorylating either a random copolymer or a random copolymeric block that contains monomeric units of propylene oxide and glycidol.

Phosphate-containing copolymers, medical compositions containing the phosphate-containing copolymers, and methods of suppressing microbial virulence are provided. By suppressing virulence, administration and/or application of the medical compositions can be used to prevent, mitigate, or treat a microbial infection. The phosphate-containing copolymers are prepared by phosphorylating either a random copolymer or a random copolymeric block that contains monomeric units of propylene oxide and glycidol.

Disclosed herein is the de novo synthesis of phosphorylated polyethylene glycol compounds with three defined ABA (hydrophilic/-phobic/-philic) structures: ABA-PEG10k-Pi10, ABA-PEG16k-Pi14, and ABA-PEG20k-Pi20 and linear polymer PEG20k-Pi20 absent of hydrophobic block. The disclosure also provides materials and methods for treating or reducing the risk or likelihood of developing, anastomotic leak or other microbe-mediated disorders by administering a therapeutically effective amount of a plasminogen inhibitor such as tranexamic acid and/or a phosphate-loaded polymer.

A perfluoropolyether phosphate ester represented by the general formula:

[C.sub.3F.sub.7O{CF(CF.sub.3)CF.sub.2O}.sub.nCF(CF.sub.3)CH.sub.2O].sub.2PO(OH)

(wherein n is an integer of 1 to 20). This compound is obtained by reacting a perfluoropolyether alcohol represented by the general formula:

C.sub.3F.sub.7O{CF(CF.sub.3)CF.sub.2O}.sub.nCF(CF.sub.3)CH.sub.2OH

(wherein n is an integer of 1 to 20) with phosphorus oxychloride, and hydrolyzing the obtained compound represented by the general formula:

[C.sub.3F.sub.7O{CF(CF.sub.3)CF.sub.2O}.sub.nCF(CF.sub.3)CH.sub.2O].sub.2POCl

(wherein n is an integer of 1 to 20). Moreover, the perfluoropolyether phosphate ester or a salt thereof forms a surface treatment agent comprising the perfluoropolyether phosphate ester or a salt thereof as an active ingredient.

A perfluoropolyether phosphate ester represented by the general formula:

[C.sub.3F.sub.7O{CF(CF.sub.3)CF.sub.2O}.sub.nCF(CF.sub.3)CH.sub.2O].sub.2PO(OH)

(wherein n is an integer of 1 to 20). This compound is obtained by reacting a perfluoropolyether alcohol represented by the general formula:

C.sub.3F.sub.7O{CF(CF.sub.3)CF.sub.2O}.sub.nCF(CF.sub.3)CH.sub.2OH

(wherein n is an integer of 1 to 20) with phosphorus oxychloride, and hydrolyzing the obtained compound represented by the general formula:

[C.sub.3F.sub.7O{CF(CF.sub.3)CF.sub.2O}.sub.nCF(CF.sub.3)CH.sub.2O].sub.2POCl

(wherein n is an integer of 1 to 20). Moreover, the perfluoropolyether phosphate ester or a salt thereof forms a surface treatment agent comprising the perfluoropolyether phosphate ester or a salt thereof as an active ingredient.

A coating composition includes a (A) binder component and a (B) pigment component. The (A) binder component includes (A1) polyvinyl butyrate, (A2) a particular film forming resin, (A3) an acid, (A4) an optional functionalized tri-alkoxy silane, and (A5) an optional polymeric phosphate ester. The (B) pigment component includes (B1) a calcium ion-exchanged silica, (B2) a corrosion inhibiting pigment, and (B3), a polyalkylene oxide phosphate. The coating composition is formed by combining the aforementioned components. In a method, the coating composition is applied to a substrate.

A coating composition includes a (A) binder component and a (B) pigment component. The (A) binder component includes (A1) polyvinyl butyrate, (A2) a particular film forming resin, (A3) an acid, (A4) an optional functionalized tri-alkoxy silane, and (A5) an optional polymeric phosphate ester. The (B) pigment component includes (B1) a calcium ion-exchanged silica, (B2) a corrosion inhibiting pigment, and (B3), a polyalkylene oxide phosphate. The coating composition is formed by combining the aforementioned components. In a method, the coating composition is applied to a substrate.

A coating composition includes a (A) binder component and a (B) pigment component. The (A) binder component includes (A1) polyvinyl butyrate, (A2) a particular film forming resin, (A3) an acid, (A4) an optional functionalized tri-alkoxy silane, and (A5) an optional polymeric phosphate ester. The (B) pigment component includes (B1) a calcium ion-exchanged silica, (B2) a corrosion inhibiting pigment, and (B3), a polyalkylene oxide phosphate. The coating composition is formed by combining the aforementioned components. In a method, the coating composition is applied to a substrate.